Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.

You may also be interested in...



Vantas Brochure Drops Safety Information, Draws Letter From FDA

Endo has received four enforcement letters from FDA since 1999 that cite a failure to include complete and accurate risk information for its products.

Endo’s Lidoderm Marketing Practices Under HHS OIG Investigation

Subpoena asks for documents relating to off-label promotion of pain patch.

Endo’s Lidoderm Marketing Practices Under HHS OIG Investigation

Subpoena asks for documents relating to off-label promotion of pain patch.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel